TO TARGET STUDY: INTERIM ANALYSIS OF A SINGLE-ARM STUDY TO ASSESS ACHIEVEMENT OF NKF-K/DOQI MINERAL METABOLISM TARGETS IN AUSTRALIAN DIALYSIS PATIENTS USING SENSIPAR®

被引：0
作者：
Masterson, R. [1 ]
Talaulikar, G. [2 ]
Mantha, M.
Jones, B. [3 ]
Bannister, K. [4 ]
Tolman, C.
Manamley, N.
机构：
[1] Royal Melbourne Hosp, Melbourne, Vic, Australia
[2] Canberra Hosp, Canberra, ACT, Australia
[3] John Hunter Hosp, Sydney, NSW, Australia
[4] Royal Adelaide Hosp, Adelaide, SA, Australia
来源：
NEPHROLOGY | 2008年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
184
引用
收藏
页码：A148 / A148
页数：1
相关论文
共 36 条
  • [21] EFFICACY AND SAFETY OF MULTI-TARGET THERAPY USING A COMBINATION OF CYCLOPHOSPHAMIDE AND TACROLIMUS IN PATIENTS WITH REFRACTORY LUPUS NEPHRITIS: A PROSPECTIVE, SINGLE-ARM, OPEN-LABEL STUDY OF 13 PATIENTS
    Sakai, R.
    Shibata, A.
    Chino, K.
    Kondo, T.
    Okuyama, A.
    Takei, H.
    Amano, K.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 1077 - 1077
  • [22] Interim results of a multicenter, single-arm study to assess Blinatumomab in adult patients (pts) with minimal residual disease (MRD) of B-precursor (BCP) acute lymphoblastic leukemia (GMALL-MOLACT1-BLINA)
    Wermann, W. K.
    Schwartz, S.
    Fiedler, W.
    Kayser, S.
    Huettmann, A.
    Alakel, N.
    Bargou, R.
    Faul, C.
    Heidenreich, D.
    Jung, W.
    Martin, S.
    Subklewe, M.
    Topp, M.
    Viardot, A.
    Vucinic, V.
    Waesch, R.
    Brueggemann, M.
    Goekbuget, N.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 174 - 175
  • [23] Interim Results of a Multicenter, Single-Arm Study to Assess Blinatumomab in Adult Patients (pts) with Minimal Residual Disease (MRD) of B-Precursor (BCP) Acute Lymphoblastic Leukemia (GMALL-MOLACT1-BLINA)
    Goekbuget, Nicola
    Wermann, Wiba Keke
    Schwartz, Stefan
    Huttmann, Andreas
    Faul, Christoph
    Raffel, Simon
    Viardot, Andreas
    Fiedler, Walter
    Alakel, Nael
    Stelljes, Matthias
    Subklewe, Marion
    Wasch, Ralph
    Martin, Sonja
    Jung, Wolfram
    Vucinic, Vladan
    Kondakci, Mustafa
    Fransecky, Lars R.
    Heidenreich, Daniela
    Wendelin, Knut
    Hermann, Julian
    Serve, Hubert
    [J]. BLOOD, 2020, 136
  • [24] The interim analysis of a single-arm, open-label, phase II study investigating ALLEN regimen (durvalumab plus albumin paclitaxel and lenvatinib) in patients with unresectable biliary tract cancers (BTCs).
    Li, Zhifang
    Chen, Meixia
    Ming, Qianyi
    Zhang, Yan
    Feng, Kaichao
    Mei, Qian
    Liu, Yang
    Han, Weidong
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 504 - 504
  • [25] A multicenter, open label, single-arm, phase 3b study (CONSONANCE) to assess efficacy of ocrelizumab in patients with primary and secondary progressive multiple sclerosis: year 1 interim analysis of cognition outcomes (P1-1.Virtual)
    Benedict, Ralph
    Sormani, Maria Pia
    McGinley, Marisa
    Arnold, Douglas
    Bar-Or, Amit
    Bermel, Robert
    Bhargava, Pavan
    Chard, Declan
    Gherardi, Guy
    Henry, Roland
    Howell, Owain
    Lebrun-Frenay, Christine
    Leocani, Letizia
    Lubetzki, Catherine
    Kazlauskaite, Agne
    Kuenzel, Thomas
    Montalban, Xavier
    Sellebjerg, Finn
    Comi, Giancarlo
    Craveiro, Licinio
    Butzkeuven, Helmut
    [J]. NEUROLOGY, 2022, 98 (18)
  • [26] A multicentre, open label, single-arm, phase 3b study (CONSONANCE) to assess the effectiveness and safety of ocrelizumab in patients with primary and secondary progressive multiple sclerosis: year-1 interim analysis (P1-1.Virtual)
    Comi, Giancarlo
    Bermel, Robert
    Bar-Or, Amit
    McGinley, Marisa
    Arnold, Douglas
    Henry, Roland
    Benedict, Ralph
    Bhargava, Pavan
    Butzkueven, Helmut
    Chard, Declan
    Gherardi, Guy
    Howell, Owain
    Lebrun-Frenay, Christine
    Leocani, Letizia
    Kazlauskaite, Agne
    Kuenzel, Thomas
    Montalban, Xavier
    Sormani, Maria Pia
    Sellebjerg, Finn
    Craveiro, Licinio
    Lubetzki, Catherine
    [J]. NEUROLOGY, 2022, 98 (18)
  • [27] A Multicenter, Multicohort, Open-Label, Single-Arm per Cohort, Phase II Study to Assess the Efficacy and Safety of Tabelecleucel in Patients with EBV-Associated Diseases Using an Adaptive Two-Stage Study Design
    Prockop, S.
    Dinavahi, R.
    Navarro, W.
    Guzman-Becerra, N.
    Sun, Y.
    Gamelin, L.
    [J]. BLOOD, 2020, 136
  • [28] Interim analysis of a single-arm, phase II study of bevacizumab (BV) with modified OPTIMOX1 as first-line treatment of patients with metastatic colorectal cancer (mCRC): TCOG-GI0802
    Asano, M.
    Tanaka, S.
    Sato, A.
    Nakayama, N.
    Shimada, K.
    Konishi, K.
    Hibi, K.
    Sasaki, E.
    Kurihara, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [29] Ruxolitinib in treatment-naive or corticosteroid-refractory paediatric patients with chronic graft-versus-host disease (REACH5): interim analysis of a single-arm, multicentre, phase 2 study
    Locatelli, Franco
    Antmen, Bulent
    Kang, Hyoung Jin
    Koh, Katsuyoshi
    Takahashi, Yoshiyuki
    Kupesiz, Alphan
    Matos, Maria Gabriela A. Dias
    Chopra, Yogi
    Bhat, Sunil
    Im, Ho Joon
    Guengoer, Tayfun
    Lu, Meng-Yao
    Stefanelli, Tommaso
    Rosko, Christine
    St Pierre, Annie
    Burock, Karin
    Smith, Yvonne
    Sinclair, Karen
    Diaz-de-Heredia, Cristina
    [J]. LANCET HAEMATOLOGY, 2024, 11 (08): : e580 - e592
  • [30] A single-arm, open-label study to assess the immunogenicity, safety, and efficacy of etanercept manufactured using the serum-free, high-capacity manufacturing process administered to patients with rheumatoid arthritis
    Polak, Pavol
    Peric, Porin
    Louw, Ingrid
    Gaylord, Stefanie M.
    Williams, Theresa
    Becker, Jean-Claude
    Pedersen, Ron
    Korth-Bradley, Joan
    Vlahos, Bonnie
    [J]. EUROPEAN JOURNAL OF RHEUMATOLOGY, 2019, 6 (01) : 23 - +
1234